Chardan Capital Initiates Coverage On Gossamer Bio with Buy Rating, Announces Price Target of $160
Chardan Capital analyst Andreas Argyrides initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Buy rating and announces Price Target of $160.
Stocks · News reference
Gossamer Bio Slides as $250M Financing Hinges on FDA Milestones
Gossamer Bio Financing could provide up to $250 million, with much of the funding tied to seralutinib FDA milestones.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Gossamer Bio, Inc. (GOSS)
Filed: 2026-09-28 AccNo: 0001728117-26-000106 Size: 138 KB Item 8.01: Other Events
Gossamer Bio Submits NDA To FDA For Seralutinib For Treatment Of Pulmonary Arterial Hypertension
– NDA Supported by the Phase 3 PROSERA Study, Phase 2 TORREY Study and Additional Supportive Analyses –Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical
HC Wainwright & Co. Maintains Buy on Gossamer Bio, Raises Price Target to $90
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Gossamer Bio (NASDAQ:GOSS) with a Buy and raises the price target from $2 to $90.